FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1884408039> ?p ?o ?g. }

• W1884408039 endingPage "9516" @default.
• W1884408039 startingPage "9516" @default.
• W1884408039 abstract "9516 Background: Background: Aggressive fibromatosis/desmoid tumors (AF/DT) are rare tumors with loco regional spreading. Few options are available when local treatments have failed. Although cytotoxic agents, hormonal treatment have been reported to induced responses and tumor control in some patients, only few prospective phase II trials have been reported in the literature. Recently, antitumor activity of imatinib in AF/DT was reported. We report a phase II trial of imatinib in AF/DT after failure of local treatment options. Methods: Pts ≥ 18 years with advanced AF/DT from all sites in whom neither surgery nor radiotherapy was possible were eligible. The principal inclusion criterias were: disease not amenable to surgery and/or radiation with curative intent, systemic pre-treatments allowed and presence of a measurable lesion with evidence of progression. Imatinib was given at the dose of 400 mg/d and increased to 800 mg/d if progression. Primary endpoint was the rate of progression free at 3 months. A two stages Simon‘s optimal design was used with p 0 =10%, p 1 =30%, α=0.05 and 90% power. 18 pts were scheduled to be recruited in the first stage for a total of 35 evaluable pts. Results: Between 09/2004 and 10/2005, 40 pts were included in 15 centers. The median age was 40 years (range 20–72) with 26% males. Primary sites were extra abdominal, mesenteric, abdominal wall in 79, 15, and 6% respectively. 15% patients had not been operated previously and 17% undergone radiotherapy. Prior systemic treatments were: NSAID, hormonal therapy or chemotherapy in 34, 46 and 23%, respectively. Median treatment duration was 4 months (range 0–12). No G4 toxicity was reported. Toxicities (G1–3) were notified for 30 pts including asthenias (70%), nauseas (53%), diarrheas, oedema (40%). G3 toxicities were abdominal pain (10%), rash, nausea, vomiting and asthenia (7%). At 3 months, 22 pts (55%) were evaluable with 1 CR, 17 SD and 4PD. As of December 2005, 7 of the 40 pts had progressed. After progression, dose was stopped in 2 pts and increased to 800mg in 5 pts with 2 tumor control following dose-escalation. Conclusions: Imatinib induces prolonged disease stabilization in the majority of evaluable patients with AF/DT in whom no local treatment option was available. [Table: see text]" @default.
• W1884408039 created "2016-06-24" @default.
• W1884408039 creator A5019588141 @default.
• W1884408039 creator A5034923505 @default.
• W1884408039 creator A5042202815 @default.
• W1884408039 creator A5042880619 @default.
• W1884408039 creator A5052242950 @default.
• W1884408039 creator A5054348966 @default.
• W1884408039 creator A5065564812 @default.
• W1884408039 creator A5085647218 @default.
• W1884408039 creator A5085936617 @default.
• W1884408039 creator A5090103193 @default.
• W1884408039 date "2006-06-20" @default.
• W1884408039 modified "2023-10-01" @default.
• W1884408039 title "Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group" @default.
• W1884408039 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.9516" @default.
• W1884408039 hasPublicationYear "2006" @default.
• W1884408039 type Work @default.
• W1884408039 sameAs 1884408039 @default.
• W1884408039 citedByCount "1" @default.
• W1884408039 crossrefType "journal-article" @default.
• W1884408039 hasAuthorship W1884408039A5019588141 @default.
• W1884408039 hasAuthorship W1884408039A5034923505 @default.
• W1884408039 hasAuthorship W1884408039A5042202815 @default.
• W1884408039 hasAuthorship W1884408039A5042880619 @default.
• W1884408039 hasAuthorship W1884408039A5052242950 @default.
• W1884408039 hasAuthorship W1884408039A5054348966 @default.
• W1884408039 hasAuthorship W1884408039A5065564812 @default.
• W1884408039 hasAuthorship W1884408039A5085647218 @default.
• W1884408039 hasAuthorship W1884408039A5085936617 @default.
• W1884408039 hasAuthorship W1884408039A5090103193 @default.
• W1884408039 hasConcept C126322002 @default.
• W1884408039 hasConcept C141071460 @default.
• W1884408039 hasConcept C142724271 @default.
• W1884408039 hasConcept C143998085 @default.
• W1884408039 hasConcept C203092338 @default.
• W1884408039 hasConcept C2775983998 @default.
• W1884408039 hasConcept C2777583451 @default.
• W1884408039 hasConcept C2778256501 @default.
• W1884408039 hasConcept C2778729363 @default.
• W1884408039 hasConcept C2779677255 @default.
• W1884408039 hasConcept C509974204 @default.
• W1884408039 hasConcept C535046627 @default.
• W1884408039 hasConcept C71924100 @default.
• W1884408039 hasConcept C90924648 @default.
• W1884408039 hasConceptScore W1884408039C126322002 @default.
• W1884408039 hasConceptScore W1884408039C141071460 @default.
• W1884408039 hasConceptScore W1884408039C142724271 @default.
• W1884408039 hasConceptScore W1884408039C143998085 @default.
• W1884408039 hasConceptScore W1884408039C203092338 @default.
• W1884408039 hasConceptScore W1884408039C2775983998 @default.
• W1884408039 hasConceptScore W1884408039C2777583451 @default.
• W1884408039 hasConceptScore W1884408039C2778256501 @default.
• W1884408039 hasConceptScore W1884408039C2778729363 @default.
• W1884408039 hasConceptScore W1884408039C2779677255 @default.
• W1884408039 hasConceptScore W1884408039C509974204 @default.
• W1884408039 hasConceptScore W1884408039C535046627 @default.
• W1884408039 hasConceptScore W1884408039C71924100 @default.
• W1884408039 hasConceptScore W1884408039C90924648 @default.
• W1884408039 hasIssue "18_suppl" @default.
• W1884408039 hasLocation W18844080391 @default.
• W1884408039 hasOpenAccess W1884408039 @default.
• W1884408039 hasPrimaryLocation W18844080391 @default.
• W1884408039 hasRelatedWork W1846464544 @default.
• W1884408039 hasRelatedWork W1884408039 @default.
• W1884408039 hasRelatedWork W1970458785 @default.
• W1884408039 hasRelatedWork W2069736720 @default.
• W1884408039 hasRelatedWork W2106365164 @default.
• W1884408039 hasRelatedWork W2119274552 @default.
• W1884408039 hasRelatedWork W2186634031 @default.
• W1884408039 hasRelatedWork W2249156300 @default.
• W1884408039 hasRelatedWork W2592334292 @default.
• W1884408039 hasRelatedWork W2598223655 @default.
• W1884408039 hasVolume "24" @default.
• W1884408039 isParatext "false" @default.
• W1884408039 isRetracted "false" @default.
• W1884408039 magId "1884408039" @default.
• W1884408039 workType "article" @default.